Zhejiang Anglikang Pharmaceutical Co Ltd Class A Net Assets
Zhejiang Anglikang Pharmaceutical Co Ltd Class A net assets. Based on the latest financial reports, Zhejiang Anglikang Pharmaceutical Co Ltd Class A (002940) has net assets worth CN¥1.90 Billion CNY (≈ $278.32 Million USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥2.98 Billion ≈ $435.47 Million USD) and total liabilities (CN¥1.07 Billion ≈ $157.14 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore 002940 shareholders equity momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.90 Billion |
| % of Total Assets | 63.91% |
| Annual Growth Rate | 21.61% |
| 5-Year Change | 26.6% |
| 10-Year Change | 470.26% |
| Growth Volatility | 39.42 |
Net Assets of Zhejiang Anglikang Pharmaceutical Co Ltd Class A (2014–2025)
Net assets of Zhejiang Anglikang Pharmaceutical Co Ltd Class A from 2014 to 2025. This chart illustrates how Zhejiang Anglikang Pharmaceutical Co Ltd Class A's net assets have evolved over time, based on quarterly financial data. See Zhejiang Anglikang Pharmaceutical Co Ltd (002940) net asset quality to measure how much of total assets are equity-financed.
Annual Net Assets for Zhejiang Anglikang Pharmaceutical Co Ltd Class A (2014–2025)
The table below shows the annual net assets of Zhejiang Anglikang Pharmaceutical Co Ltd Class A from 2014 to 2025. For live market cap and overall valuation, see how much is Zhejiang Anglikang Pharmaceutical Co Ltd worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥1.87 Billion ≈ $273.23 Million |
+3.83% |
| 2024-12-31 | CN¥1.80 Billion ≈ $263.17 Million |
-1.85% |
| 2023-12-31 | CN¥1.83 Billion ≈ $268.12 Million |
+11.31% |
| 2022-12-31 | CN¥1.65 Billion ≈ $240.88 Million |
+11.61% |
| 2021-12-31 | CN¥1.47 Billion ≈ $215.83 Million |
+7.04% |
| 2020-12-31 | CN¥1.38 Billion ≈ $201.64 Million |
+35.56% |
| 2019-12-31 | CN¥1.02 Billion ≈ $148.74 Million |
+4.69% |
| 2018-12-31 | CN¥970.93 Million ≈ $142.08 Million |
+146.20% |
| 2017-12-31 | CN¥394.37 Million ≈ $57.71 Million |
+20.44% |
| 2016-12-31 | CN¥327.43 Million ≈ $47.91 Million |
+23.93% |
| 2015-12-31 | CN¥264.20 Million ≈ $38.66 Million |
+21.70% |
| 2014-12-31 | CN¥217.08 Million ≈ $31.77 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Zhejiang Anglikang Pharmaceutical Co Ltd Class A's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 71787898087.0% over the analyzed period, indicating profitable operations and earnings retention.
Zhejiang Anglikang Pharmaceutical Co Ltd Class A Net Assets Breakdown (December 2025)
Zhejiang Anglikang Pharmaceutical Co Ltd Class A net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥709.12 Million | 43.58% |
| Other Components | CN¥918.16 Million | 56.42% |
| Total Equity | CN¥1.63 Billion | 100.00% |
Zhejiang Anglikang Pharmaceutical Co Ltd Class A Competitors by Market Cap
The table below lists competitors of Zhejiang Anglikang Pharmaceutical Co Ltd Class A ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Team Group Inc
TW:4967
|
$697.31 Million |
|
Zhuhai Enpower Electric Co Ltd
SHE:300681
|
$697.31 Million |
|
Regional Container Lines Public Company Limited
BK:RCL-R
|
$697.45 Million |
|
Sinodata Co Ltd
SHE:002657
|
$697.64 Million |
|
Attovia Therapeutics, Inc. Common Stock
NASDAQ:ATTO
|
$697.09 Million |
|
Chengdu ALD Aviation Manufacturing Corp
SHE:300696
|
$697.08 Million |
|
CEWE Stiftung & Co. KGaA
XETRA:CWC
|
$697.08 Million |
|
Israel Shipyards Ltd
TA:ISHI
|
$697.05 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Zhejiang Anglikang Pharmaceutical Co Ltd Class A's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,530,549,492 to 1,627,273,164, a change of 96,723,672 (6.3%).
- Net income of 125,441,398 contributed positively to equity growth.
- Dividend payments of 57,601,236 reduced retained earnings.
- Other comprehensive income decreased equity by 115,448,298.
- Other factors increased equity by 144,331,808.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥125.44 Million | +7.71% |
| Dividends Paid | CN¥57.60 Million | -3.54% |
| Other Comprehensive Income | CN¥-115.45 Million | -7.09% |
| Other Changes | CN¥144.33 Million | +8.87% |
| Total Change | CN¥- | 6.32% |
Book Value vs Market Value Analysis
This analysis compares Zhejiang Anglikang Pharmaceutical Co Ltd Class A's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.93x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 18.64x to 2.93x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2014-12-31 | CN¥1.27 | CN¥23.62 | x |
| 2015-12-31 | CN¥1.75 | CN¥23.62 | x |
| 2016-12-31 | CN¥2.19 | CN¥23.62 | x |
| 2017-12-31 | CN¥2.61 | CN¥23.62 | x |
| 2018-12-31 | CN¥6.15 | CN¥23.62 | x |
| 2019-12-31 | CN¥5.10 | CN¥23.62 | x |
| 2020-12-31 | CN¥6.94 | CN¥23.62 | x |
| 2021-12-31 | CN¥6.78 | CN¥23.62 | x |
| 2022-12-31 | CN¥7.57 | CN¥23.62 | x |
| 2023-12-31 | CN¥7.91 | CN¥23.62 | x |
| 2024-12-31 | CN¥7.66 | CN¥23.62 | x |
| 2025-12-31 | CN¥8.07 | CN¥23.62 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Zhejiang Anglikang Pharmaceutical Co Ltd Class A utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 7.71%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 8.80%
- • Asset Turnover: 0.48x
- • Equity Multiplier: 1.81x
- Recent ROE (7.71%) is below the historical average (15.20%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | 27.77% | 7.36% | 0.93x | 4.05x | CN¥32.08 Million |
| 2015 | 25.87% | 8.27% | 0.97x | 3.23x | CN¥39.28 Million |
| 2016 | 26.44% | 12.24% | 0.92x | 2.34x | CN¥51.10 Million |
| 2017 | 27.31% | 11.58% | 0.96x | 2.45x | CN¥64.07 Million |
| 2018 | 11.83% | 8.66% | 0.85x | 1.60x | CN¥16.79 Million |
| 2019 | 11.63% | 8.04% | 1.01x | 1.44x | CN¥15.76 Million |
| 2020 | 12.41% | 12.69% | 0.66x | 1.47x | CN¥31.83 Million |
| 2021 | 8.95% | 8.68% | 0.66x | 1.56x | CN¥-14.04 Million |
| 2022 | 8.47% | 8.12% | 0.60x | 1.73x | CN¥-22.97 Million |
| 2023 | 8.72% | 8.54% | 0.54x | 1.90x | CN¥-20.25 Million |
| 2024 | 5.25% | 5.31% | 0.51x | 1.94x | CN¥-72.72 Million |
| 2025 | 7.71% | 8.80% | 0.48x | 1.81x | CN¥-37.29 Million |
Industry Comparison
This section compares Zhejiang Anglikang Pharmaceutical Co Ltd Class A's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $3,632,405,673
- Average return on equity (ROE) among peers: 7.53%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Zhejiang Anglikang Pharmaceutical Co Ltd Class A (002940) | CN¥1.90 Billion | 27.77% | 0.56x | $697.24 Million |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $1.97 Billion | 4.04% | 0.54x | $488.97 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $560.87 Million | 4.60% | 0.22x | $360.39 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $1.02 Billion | 12.46% | 0.13x | $4.73 Billion |
| Livzon Pharmaceutical Group Inc (000513) | $1.04 Billion | 4.29% | 0.46x | $2.58 Billion |
| Wedge Industrial Co Ltd (000534) | $0.00 | 0.00% | 0.00x | $1.20 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $18.14 Billion | 17.33% | 0.53x | $14.52 Billion |
| Hainan Haiyao Co Ltd (000566) | $491.82 Million | 6.71% | 1.19x | $755.58 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $280.91 Million | 1.46% | 1.58x | $272.98 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $5.57 Billion | 7.36% | 1.59x | $920.83 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $7.25 Billion | 17.08% | 0.09x | $3.02 Billion |
About Zhejiang Anglikang Pharmaceutical Co Ltd Class A
Zhejiang AngLiKang Pharmaceutical CO.,LTD. engages in the research, development, production, and sale of pharmaceuticals in China and internationally. The company offers chemical raw materials for pharmaceuticals comprising oral cephalosporin antibiotic raw materials, including cephalexin, cefadroxil, cefaclor, and cefadroxil; alpha-keto acid raw materials; inhaled anesthetic raw materials, such … Read more